Lilly counts on growing markets to boost lagging Taltz, Trulicity

Eli Lilly is counting on Type 2 diabetes drug Trulicity and immunology launch Taltz to keep rolling amid challenges elsewhere. But both meds missed Wall Street's expectations, prompting questions from analysts.